Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
U*Night - The UNITA Researchers' Night (U-Night)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Italy,Portugal,France,Romania,Spain
Call: European Researchers' Night 2022-2023 (HORIZON-MSCA-2022-CITIZENS-01, 2022)
Start date: 2022-03-01
End date: 2024-02-29
Duration (months): 24.0
Total project cost (EUR): 422857.14
EU funding (EUR): 395000.0
Participants: 36
Project status: CLOSED

The key of U*Night is inclusiveness. The project is designed to expand the outreach action of the European Researchers’ Night and maximize its impact, bringing the event to new cities and to rural, semi-rural and mountain areas that are usually less involved in this kind of event. This is possible thanks to the participation in U*Night of the members of UNITA, one of the European University Alliance, strongly committed to the valorisation of rural and mountain areas. The activities are conceived to increase the public recognition of R&D in terms of impact on citizens and communities’ daily lives: to this aim, the project will embrace the approach of Horizon Europe Missions, framing the communication in a challenge-based narrative, that translate critical issues into concrete objectives and make the researchers’ work tangible and linked to real life. U*Night will also enhance the direct participation of people to the research process, by launching a transnational citizen science project to highlight the contribution that citizens can bring to science and the benefit they can get in terms of personal development. U*Night will also promote the role of citizens as key stakeholders in the debate on societal challenges and will activate a constructive interaction with policy makers and scientists. To this aim U*Night will create concrete opportunities for opening this dialogue, by launching co-creation processes that lead to more inclusive decision policy-making. U*Night will also develop innovative training resources to support researchers in becoming better listeners to citizens’ needs and concerns and to build a stronger relationship with society. U*Night intends finally to become an open laboratory for communication and outreach practices, where the partners can pioneer innovative actions but also nurture a stronger culture of public engagement within the European academia through the direct connection of UNITA with all the other European university Alliances

Keywords: inclusiveness,expansion,learning experience,
Tracking Hydrates In Refined Sub-neptunes to Tackle their Emergence and Evolution (THIRSTEE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Universe Sciences
Panel description: Astro -physics/ -chemistry/ -biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: Spain
Call: ERC STARTING GRANTS (ERC-2024-STG, 2024)
Start date: 2025-08-01
End date: 2030-07-31
Duration (months): 60.0
Total project cost (EUR): 1478665.0
EU funding (EUR): 1478665.0
Participants: 1
Project status: SIGNED

THIRSTEE is a ground-breaking project focusing on sub-Neptunes, a class of planets with masses and radii between those of Earth and Neptune. These planets are the most common in the Galaxy, especially around Sun-like stars, but the most basic questions about their origin and nature remain unanswered. Are sub-Neptunes "gas dwarfs" (Earth-like cores surrounded by large hydrogen-rich envelopes formed near their observed close-in locations) or "water worlds" (planets formed beyond the snow line composed of a 1:1 mixture of ice and rock)? If the latter exist, what are their demographic and individual properties and how do they depend on stellar host type? Do any of them harbour liquid water oceans below their atmospheres? The gas dwarf hypothesis has the most traction in the field, but recent evidence suggests the existence of water worlds. The observations, however, can be explained by both scenarios due to the modelling degeneracies that surround these planets. THIRSTEE aims to solve this debate using a multi-technique approach combining transit, radial velocity and atmospheric characterization data with a novel statistical framework that accounts for observational biases. This dataset constitutes a valuable addition to the community, enlarging the known sample into unexplored regions of the parameter space and enabling a direct comparison with synthetic planet populations. THIRSTEE is designed to mitigate all the shortcomings that have prevented previous studies from reaching conclusive results about this enigmatic population. For the first time, such an ambitious program can be pursued thanks to the simultaneous operation of state-of-the-art observational facilities. The project seeks to answer key questions about sub-Neptune formation and evolution, their atmospheres, and their demographic properties. Thanks to its unique approach, THIRSTEE will revolutionize our understanding of sub-Neptunes and their potential significance in the search for life beyond Earth.
RecoSMA: Breakthrough Laser Innovation for Healing and Preventing Diabetic Foot Ulcers and Chronic Wounds (RecoSMA - Wound Cure)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Latvia
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Founded in 2020 in Riga, LINLINE Medical Systems specializes in medical laser devices. They have developed solid-state pulsed lasers with unique generation modes and conducted extensive pre-clinical and clinical studies. Their flagship product, the Multiline laser platform, offers over 50 medical applications. By 2023, the company had achieved ISO 13485 certification and CE marking. LINLINE aims to lead in medical laser technology, revolutionizing Wound Care. The proprietary RecoSMA method has proven effective for treating non-healing wounds and promoting tissue regeneration. Collaborations with top medical centres in Europe and Asia support their clinical success. Diabetic Foot Ulcers present a significant healthcare burden with high treatment costs. Current treatments often fail, leading to high amputation rates and mortality. LINLINE's two-step laser-based approach—wound debridement and bio-stimulation—offers a revolutionary solution. LINLINE's technology provides outpatient, pain-free, fast wound treatment, reducing labour costs and improving healing rates. It shifts focus from managing to curing and preventing wounds, significantly impacting healthcare sustainability and patient outcomes. The technology aligns with EU and UN sustainability goals, promoting innovation, reducing inequalities, and supporting good health and well-being. LINLINE's team includes experts in laser technology, medical applications, clinical research, production, customer service, and regulatory affairs. LINLINE seeks EIC support to overcome financial hurdles and advance its technology to market readiness. They aim to raise €5 million for clinical trials, R&D, and marketing. This support will help secure additional investments and scale their operations, aligning with EIC goals of fostering high-potential innovations.

Keywords: wound care,chronic wounds,diabetic foot ulcers,medical devices,laser technology,diabetes,surgery
Support for the activities of the European Group on Ethics (EGE) by European Academia and Ethics Bodies (SAEGE)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Reforming and enhancing the European R&I System
Theme: Euratom
Destination: Euratom
Action type: Coordination and support actions
Countries involved: Germany
Call: Support for the Activities of the European Group on Ethics (EGE) by European Academia and Ethics Bodies (SAEGE) (HORIZON-EURATOM-2025-EGE, 2025)
Start date: 2025-11-01
End date: 2029-10-31
Duration (months): 48.0
Total project cost (EUR): 4999600.0
EU funding (EUR): 4996750.0
Participants: 1
Project status: SIGNED

SAEGE is a Horizon Europe project that enhances the integration of ethical insight into EU policymaking in response to rapid developments in science and technology. The overall goal of SAEGE is to support the European Group on Ethics in Science and New Technologies (EGE) in its mission to advise the European Commission (EC) on all aspects of EU policy and legislation where ethical, societal, and fundamental rights dimensions intersect with the development of science and new technologies. As innovations increasingly affect social norms, human rights, and the environment, SAEGE helps ensure that ethics remains central to science governance in the EU. SAEGE provides structured, ethics-based evidence and analysis to inform the EGE’s advice. This includes literature reviews, expert consultations, stakeholder workshops, and full evidence review reports that translate diverse inputs into policy-relevant ethical assessments. The project aligns with the EGE’s 2021 call for ethics rooted in “comprehensive and pluralistic thinking,” informed by sound science, critical analysis, and inclusive societal debate. To support this vision, SAEGE is developing the EGE Et Alia Advisory Network (EGEAN), which connects the EGE with actors in the ethics and science advise landscape. The EGEAN will support SAEGE’s work through stakeholder mapping, an online hub, and ethics policy briefings. To anticipate future issues, SAEGE will also implement a horizon scanning and early alert system using tools such as social media trend analysis, web scraping, and text mapping. These insights will be distilled into Horizon Scanning Briefs to inform proactive, ethically grounded EU policymaking.

Keywords: ethics advice,research ethics,eu policymaking,ege,science governance,human rights,ethical assessments,egean,stakeholder engagement,horizon scanning,evidence based policy,innovation ethics
Carbon Atmospheric Tracer Research to Improve Numerics and Evaluation (CATRINE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Space
Destination: Open Strategic Autonomy in Developing, Deploying and Using Global Space-Based Infrastructures, Services, Applications and Data
Action type: Research and Innovation actions
Countries involved: United Kingdom,France,Netherlands,Germany,Finland
Call: Copernicus for Atmosphere and Climate Change, including CO2 (HORIZON-CL4-2023-SPACE-01, 2023)
Start date: 2024-01-01
End date: 2026-12-31
Duration (months): 36.0
Total project cost (EUR): 2996289.69
EU funding (EUR): 2996289.69
Participants: 8
Project status: SIGNED

The CATRINE project will focus on the atmospheric tracer transport research areas identified by the EU's CO2 Task Force, the CO2 Human Emissions (CHE) project, and the Copernicus CO2 service (CoCO2) projects. The accuracy and mass conservation of the tracer transport model is of utmost importance in the design of the CO2MVS. Any unaccounted systematic errors in the tracer transport model can lead to inaccuracies in the estimation of CO2 and other tracer emissions. Therefore, CATRINE aims to improve the methods used to represent resolved tracer transport by the winds, with a particular focus on mass conservation, and to identify other systematic errors associated with unresolved processes represented by parametrizations. The project will define protocols for evaluating tracer transport models at both global and local scales. Test beds based on field campaign case studies will be developed, along with suitable metrics for tracer transport evaluation, utilising a range of tracers and observations at both global and local scales. These metrics will be employed in the operational CO2MVS to evaluate the implementation of new transport model developments, characterise transport accuracy and representativity in data assimilation, and provide a quality control stamp of tracer transport accuracy. Lastly, CATRINE will provide clear recommendations to the CO2MVS and the Carbon Cycle Community which works with atmospheric inversion models for the evaluation and quality assessment of tracer transport models.

Keywords: greenhouse gas flux inversions co2mvs atmospheric tracer transport modelling
Understanding Precancerous changes in BReast CAncer for the development of Therapeutic interceptions (PreBRCATx)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: United Kingdom
Call: ERC ADVANCED GRANTS (ERC-2024-ADG, 2024)
Start date: 2025-11-01
End date: 2030-10-31
Duration (months): 60.0
Total project cost (EUR): 2499112.0
EU funding (EUR): 2499112.0
Participants: 1
Project status: SIGNED

In this programme, we will leverage our understanding of the cellular and molecular changes that precede cancer in high-risk individuals to intercept and prevent the development of the disease. Despite significant advances in immune and targeted therapies, the molecular and cellular complexity of late-stage tumours continues to pose a major barrier to developing a definitive “cancer cure”. This underscores the urgency of identifying those at risk and intervening prophylactically to prevent tumour development. Early detection and interception can significantly enhance the long-term survival of patients. Over the past decade, we have utilised a combination of single-cell genomics, mouse models, and primary human samples to map cellular changes in the breast during homeostasis and tumour initiation. Building on this expertise, we aim to deepen our understanding of precancerous changes driven by BRCA1, BRCA2, and PALB2 mutations, test the efficacy of approved and nearly approved drugs, and develop and test a preventative vaccine in pre-clinical models for these mutations. The PreBRCATx integrated approach is designed to deliver significant impacts for individuals at high risk of breast cancer and, if successful, could serve as a model for other types of hereditary cancers in the future. We aim to gather sufficient evidence to initiate clinical prevention trials, focusing on women with pathological variants of BRCA1, BRCA2, and PALB2 and we anticipate setting up a window of opportunity trial by the end of the programme. The programme will also generate new tools, resources, and data, empowering others in the breast cancer field and benefiting researchers of other solid cancers. Early detection and prevention of cancer could significantly mitigate the socioeconomic impact of late-stage cancer diagnoses and treatments, aligning with the ambitions of policymakers and healthcare providers across Europe to promote a healthier and longer life.

Keywords: biology to prevention,therapeutic prevention,early cancer interception,cancer vaccines
Aggregate and Idiosyncratic Risk in Macroeconomics (AIRMAC)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Individuals, Markets and Organisations
Panel description: Economics, finance , management
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-01-01
End date: 2028-12-31
Duration (months): 60.0
Total project cost (EUR): 1490625.0
EU funding (EUR): 1490625.0
Participants: 1
Project status: SIGNED

Since the Great Recession of 08/09, two interrelated economic phenomena challenge politics and research alike. First, the return of aggregate volatility marking the end of the Great Moderation. Second, the rise in inequality to levels last seen during the Gilded Age. A new literature has responded to this challenge by adding heterogeneity to business cycle models (HANK). This is a major step, but the focus on certainty-equivalent solutions in aggregates restricts the interaction of both phenomena. My research agenda aims to make ground-breaking progress by developing a new computational toolbox that allows to study the relative strength of aggregate and idiosyncratic risks and their interaction in inequality, asset returns, and business cycles. Part I develops a sparse higher-order perturbation solution for HANK models. Smart use of the modularity of idiosyncratic and aggregate model components makes estimation feasible, which is key for quantification. Part II measures heterogeneity in the exposure to aggregate risk and quantifies its contribution inequality. The volatility of wages, portfolio returns, and tax rates differs across the distribution, and this affects inequality via household portfolio decisions. Part III decomposes the capital premium into the parts coming from idiosyncratic and aggregate risk. Large parts of the capital stock feature trading costs that can explain part of the equity premium, which makes the equity premium puzzle less severe. Part IV examines the cost of business cycles and novel benefits of stabilization policies. By reducing aggregate risk, policy allows households to hold less liquid portfolios and increase investment into capital. Part II-IV contribute to fundamental questions in macroeconomics: the welfare costs of business cycles, the benefits of fiscal vs. monetary stabilization, and the drivers of inequality and asset returns. My agenda is ambitious, but the importance of the questions imply an extremely high return.

Keywords: heterogeneous agents,incomplete markets,business cycles,uncertainty,inequality,computational methods,monetary policy,fiscal policy,asset pricing
Organizing Towards a strengthened European cooperation in Brain health research conference under the Hungarian presidency (HUPRES-BRAIN)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Other health destinations
Action type: Coordination and support actions
Countries involved: Hungary
Call: Presidency event - Hungary. Hungarian conference on Brain health (HORIZON-HLTH-2024-PHUN-15-IBA, 2024)
Start date: 2024-09-01
End date: 2025-01-31
Duration (months): 5.0
Total project cost (EUR): 298250.0
EU funding (EUR): 298250.0
Participants: 1
Project status: SIGNED

The brain, its functions and its complexity despite intensive research efforts globally, still remains a mystery, especially when it comes to preserving its health. Brain health is an emerging and growing concept that encompasses neural development, plasticity, functioning, and recovery including mental health aspects in a life course perspective. Numerous interconnected social, environmental, life style choices and biological determinants (incl. genetics) play a role in brain development and brain health throughout the life course. Recent developments in our society e.g. aging populations, the COVID pandemic, environmental pollution, unhealthy nutrition and lifestyle, lack of exercise have increasing negative impact on brain health. By addressing a topic highly important for the European society, the conference aims at promoting the importance of multistakeholder approach in order to maximize societal impact of Brain Health research, gather feedback on challenges and good practices of cooperation and discuss possible ways towards an effective and dynamic pan-European research and innovation cooperation. The conference will provide various plenary and interactive formats for engaging stakeholders, also workshops, site visits and side-events

Keywords: health brain health presidency conference
The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine (UNDINE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Tackling diseases and reducing disease burden
Action type: Research and Innovation actions
Countries involved: Denmark,France,Belgium,Italy,Spain,Sweden,Germany,Greece,Ireland,United Kingdom,Netherlands,Estonia,Switzerland
Call: Personalised medicine and infectious diseases: understanding the individual host response to viruses (e.g. SARS-CoV-2) (HORIZON-HLTH-2021-DISEASE-04, 2021)
Start date: 2022-06-01
End date: 2026-05-31
Duration (months): 48.0
Total project cost (EUR): 6718138.75
EU funding (EUR): 6718138.75
Participants: 22
Project status: SIGNED

The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variability is the key scientific and medical enigma in the field. While age and certain co-morbidities are known to influence disease outcome, these parameters do not explain all variation. In addition, there are other SARS-CoV-2 phenotypes of clinical importance: multisystem inflammatory syndrome in children and adults (MIS-C/A), and longCOVID. An important breakthrough to unravel the pathogenesis of COVID-19 came from our two Science papers that were recognized by Nature among the top 10 discoveries of 2020. We found that about 4% of patients with critical COVID-19 pneumonia had inborn errors of immunity (IEI) that impair TLR3- and IRF7-dependent type I interferon (IFN) immunity and at least 10% of the patients carried pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs. These findings pave the way for further studies of COVID-19 pneumonia and other SARS-CoV-2 infection phenotypes and form the basis of the present research proposal, UNDINE, which follows a "bed side to bench" and "bench to bed side" approach, with the following objectivies i) to decipher the genetic and immunological basis of the various SARS-CoV-2 disease manifestations, to identify individuals at increased risk of critical COVID-19, post-infectious immunological complications, and vaccine failure iii) to develop ready-to-use diagnostic tests for large-scale detection of auto-Abs to type I IFNs and propose novel preventive and therapeutic approaches, based on the pathogenesis of SARS-CoV-2 infection for translation into personalised medicine. To achieve these goals, our project will coordinate a European multidisciplinary and translational research effort relying on a strong and synergistic combination of assets, including unique cohorts from 11 EU countries and state-of-the art human genetic, immunological and virological expertises and technologies.

Keywords: human genetics interferon,sars cov 2 autoantibodies variant of concern vaccine failure treatment translational medicine immune pathogenesis diagnostic tests inborn error of immunity